

**Information for Connecticut Prescribing Practitioners and Pharmacists Provided Pursuant to
Connecticut Public Act No. 23-171 (Effective October 1, 2023)**

In accordance with Connecticut Public Act No. 23-171, TG Therapeutics, Inc. is disclosing to prescribing practitioners and pharmacists in Connecticut certain required “list price,” or wholesale acquisition cost (“WAC”), information for its marketed prescription drug, BRIUMVI. The information provided herein is accurate as of the effective date of this notice.

The price listed below is the WAC price for each NDC-11 of BRIUMVI, established and made available to the public by a third-party publisher. This WAC price represents TG Therapeutics’ published list price for each BRIUMVI NDC-11 sold to wholesalers before any prompt pay or other discounts, rebates, or reductions in price. The listed WAC price may differ significantly from the actual prices paid by customers and consumers for BRIUMVI. In addition, a product’s WAC price is typically not associated with per-dose pricing, and does not necessarily reflect the price per dosage, price per course of treatment, or the cost effectiveness of BRIUMVI.

Please refer to the BRIUMVI website www.briumvi.com for additional information about the product, including its FDA-approved prescribing information.

NDC-11	Drug Name and Description	WAC*
73150-0150-06	BRIUMVI (ublituximab-xiiy) 150 mg/6 mL Vial	\$ 11,832.15

For more information on the price disclosure requirements, please contact the Connecticut State Board of Pharmacy at:

State Board of Pharmacy
450 Columbus Blvd
Hartford, CT 06103
Ph. (860) 713-6070
Website: <https://portal.ct.gov/DCP/DrugControl-Division/Commission-of-Pharmacy/The-Commission-of-Pharmacy>

* WAC price as of January 5, 2026.

BRIUMVI is a trademark of TG Therapeutics, Inc.

Last updated: January 5, 2026.